anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
People with type 1 diabetes (T1D) are recommended to engage in regular exercise for a variety of health and fitness reasons. However, moderate-intensity exercise is associated with an increased risk of hypoglycaemia in people with T1D. Current guidelines are to reduce insulin dose and/or increase carbohydrate consumption in the context of the exercise bout. However, despite the many advances in insulin formulations and delivery devices, hypoglycaemia remains a significant risk. Mini-dose glucagon taken before an exercise bout has been shown to be an effective non-caloric strategy to prevent exercise-induced hypoglycaemia. However, even the reduced doses (150-200 µg) used in previous studies might still be rather high translating into potential side-effects (i.e. hyperglycaemia, gastrointestinal symptoms, etc.). Lower doses (below 100 µg, micro-glucagon) may be sufficiently effective to counteract hypoglycaemia risk associated with exercise and associated with better tolerance. Moreover, there is little information on the effects of subcutaneous glucagon on glycogen stores and changes in exercise metabolism. Greater understanding of exercise-associated metabolism following mini- and micro-dose glucagon using techniques such as magnetic resonance spectroscopy (MRS), continuous glucose monitoring (CGM), stable isotope tracers, and indirect calorimetry may result in novel approaches to improve blood glucose management in people with T1D. Utilising these techniques may also further our understanding of the optimal glucagon dosing (timing and amount) during exercise to manage hypoglycaemia and reduce the risk of adverse events. Proof-of-principle study to assess effects of different doses (mini and micro) of subcutaneous glucagon analog Dasiglucagon (Zealand Pharma, Copenhagen, Denmark) on the change in blood glucose concentration during moderate-intensity exercise in people with T1D. Secondly, to investigate exercise-metabolism following Dasiglucagon injection using 3 tesla magnetic resonance spectroscopy (MRS) and indirect calorimetry. Third, to assess participant experience of Dasiglucagon during exercise and the incidence of adverse events.
NEW MATERIAL:Compounds of formula I [R<1> is 2,3-dihydrobenzothienyl or benzothienyl; R<2> is 2,3-dihydrobenzothienyl, benzothienyl or formula II (R<4> is lower alkoxy or lower alkylthio); R<3> is lower alkyl or (halogen-substituted) phenyl]. EXAMPLE:4,5-Bis(2,3-dihydro-5-benzothienyl)-2-t-butylimidazole. USE:An antiinflammatory agent, an analgesic and an antipyretic having low side effects and a high safety. PREPARATION:An aldehyde of formula R<1>CHO and another aldehyde of formula R<2>CHO are condensed in a hydrous organic solvent in the presence of a metallic cyanide such as sodium cyanide as a catalyst to obtain a compound of formula III. The resultant compound is then allowed to react with an oxidizing agent in an organic solvent to obtain a compound of formula IV. The obtained compound is subsequently subjected to a reaction with an aldehyde of formula R<3>CHO or an equivalent compound thereto in the presence of excess ammonia or ammonium salt in an organic solvent.
Retinal Pathology in Rats

Pathologic changes (degeneration and loss of photoreceptor cells) were observed in the retina of albino rats in the 2-year carcinogenicity study with pramipexole. These findings were first observed during week 76 and were dose-dependent in animals receiving 2 or 8 mg/kg/day (plasma AUCs equal to 2.5 and 12.5 times that in humans at the MRHD). In a similar study of pigmented rats with 2 years exposure to pramipexole at 2 or 8 mg/kg/day, retinal degeneration was not observed. Animals given drug had thinning in the outer nuclear layer of the retina that was only slightly greater (by morphometric analysis) than that seen in control rats.

Investigative studies demonstrated that pramipexole reduced the rate of disk shedding from the photoreceptor rod cells of the retina in albino rats, which was associated with enhanced sensitivity to the damaging effects of light. In a comparative study, degeneration and loss of photoreceptor cells occurred in albino rats after 13 weeks of treatment with 25 mg/kg/day of pramipexole (54 times the MRHD on a mg/m2 basis) and constant light (100 lux) but not in pigmented rats exposed to the same dose and higher light intensities (500 lux). Thus, the retina of albino rats is considered to be uniquely sensitive to the damaging effects of pramipexole and light. Similar changes in the retina did not occur in a 2-year carcinogenicity study in albino mice treated with 0.3, 2, or 10 mg/kg/day (0.3, 2.2 and 11 times the MRHD on a mg/m2 basis). Evaluation of the retinas of monkeys given 0.1, 0.5, or 2 mg/kg/day of pramipexole (0.4, 2.2, and 8.6 times the MRHD on a mg/m2 basis) for 12 months and minipigs given 0.3, 1, or 5 mg/kg/day of pramipexole for 13 weeks also detected no changes.

The potential significance of this effect in humans has not been established, but cannot be disregarded because disruption of a mechanism that is universally present in vertebrates (i.e., disk shedding) may be involved.

Fibro-osseous Proliferative Lesions in Mice

An increased incidence of fibro-osseous proliferative lesions occurred in the femurs of female mice treated for 2 years with 0.3, 2.0, or 10 mg/kg/day (0.3, 2.2, and 11 times the MRHD on a mg/m2 basis). Similar lesions were not observed in male mice or rats and monkeys of either sex that were treated chronically with pramipexole. The significance of this lesion to humans is not known
The present invention relates to ophthalmology, particularly to the method of manufacturing of eye drops from autologous or alogenic venous blood or umbilical cord blood plasma or serum, and their use for the treatment of ocular surface disorders. The method is characterized by centrifuging of venous blood collected from the patient or umbilical cord blood from the donor and isolating two blood fractions: serum or plasma above and erythrocytes below. Just serum or plasma is used for the manufacturing of eye drops. Serum or plasma is filtered through a 0.2 micrometer filter and diluted with physiological solution and a 10% eye drop solution is manufactured. Alternatively, blood serum or plasma is added to a tube with physiological solution and a 10% concentration eye drop solution is prepared, then the solution is filtered through a sterile 0.2 micrometer filter. The obtained eye drop solution is added to sterile tubes and stored up to -80°C for up to 6 months. Before the application, eye drops are thawed to +17oC - +25oC. The eye drops of the present invention are intended for the treatment of ocular surface disorders, such as dry eye syndrome or persisting corneal epithelium defects.
BACKGROUND: Insomnia is very common in psychiatric disorders, but the polysomnographic (PSG) characteristics of insomnia in various psychiatric disorders are still not agreed upon. This study aimed to investigate the characteristics of PSG and its relationship with metabolic indicators in insomnia patients with affective disorders and primary insomnia (PI) patients.
METHODS: A total of 38 patients with PI, 44 major depressive disorder patients with insomnia (DI), 49 generalized anxiety disorder patients with insomnia (GI), and 19 bipolar mania patients with insomnia (BI) were included. PSG was used to detect sleep problems in subjects, and biochemical indicators were also collected.
RESULTS: The results of this study found that subjects with BI were lower on REM sleep latency (RL), awakenings number (AN), number of microarousals (NM), and apnea-hypopnea index (AHI) than those with DI and GI, and lower on RL and AN than those with PI. Subjects with PI had lower NM and AHI than those with DI and GI. Patients with DI had a higher RL than those with GI. All results passed Bonferroni correction (p < 0.00078). No differences in biochemical indices were found among the four groups of subjects. Also, AHI was found to be positively correlated with free triiodothyronine (FT3) and fasting blood glucose in subjects.
CONCLUSION: This study suggests that various psychiatric disorders may have their characteristics in terms of PSG parameters, which prompted us to focus on the PSG characteristics of these disorders when assessing them, as well as to focus on their biochemical indicators.
Huaier Granule will be administrated from 4 to 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
Apheresis is a modern medical approach in which plasma or cellular components are separated from the whole blood. Apheresis can be either diagnostic or therapeutic. Diagnostic apheresis is typically applied in hematology and cancer research. Therapeutic Apheresis (TA) includes a broad spectrum of extracorporeal treatments applied in various medical specialties, including Intensive Care Unit (ICU). Considering the complexity of the pathophysiologic characteristics of various clinical entities and in particular sepsis, apheresis methods are becoming increasingly applicable. Therapeutic Plasma Exchange (TPE) is the most common used method in ICU. It is considered as first line therapy for Thrombotic Thrombocytopenic Purpura (TTP) and Guillain Barre Syndrome, while the current data for sepsis are scarce. Over the last decades, technologic evolution has led to increasing application of new and more selective methods based on adsorptive techniques. In this review we will describe the current data of characteristics of different techniques, safety and clinical impact of apheresis methods used in ICUs.
OBJECTIVE: To describe strategies used to maximise follow-up after a neonatal randomised trial, how these differed for families of different ethnicity, socioeconomic status and urban versus rural residence and investigate relationships between the difficulty of follow-up and rate of neurosensory impairment.
METHOD: hPOD was a multicentre randomised trial assessing oral dextrose gel prophylaxis for neonatal hypoglycaemia. Follow-up at 2 years was conducted from 2017 to 2021. We analysed all recorded contacts between the research team and participants' families. Neurosensory impairment was defined as blindness, deafness, cerebral palsy, developmental delay or executive function impairment.
RESULTS: Of 1321 eligible participants, 1197 were assessed (91%) and 236/1194 (19.8%) had neurosensory impairment. Participants received a median of five contacts from the research team (range 1-23). Those from more deprived areas and specific ethnicities received more contacts, particularly home tracking visits and home assessments. Impairment was more common among participants receiving more contacts (relative risk 1.81, 95% CI 1.34 to 2.44 for ≥7 contacts vs <7 contacts), and among those assessed after the intended age (76/318, 23.9% if >25 months vs 160/876, 18.3% if ≤25 months).
CONCLUSIONS: Varied contact strategies and long timeframes are required to achieve a high follow-up rate. Without these, the sociodemographics of children assessed would not have been representative of the entire cohort, and the rate of neurosensory impairment would have been underestimated. To maximise follow-up after randomised trials, substantial effort and resources are needed to ensure that data are useful for clinical decision-making.
This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., "Sleep", "Nutrition", "Healthy Weight" and "Medical appointments". The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
Neurological diseases with a neurodegenerative component have been associated with alterations in the cerebrovasculature. At the anatomical level, these are centred around changes in cerebral blood flow and vessel organisation. At the molecular level, there is extensive expression of cellular adhesion molecules and increased release of pro-inflammatory mediators. Together, these has been found to negatively impact blood-brain barrier integrity. Systemic inflammation has been found to accelerate and exacerbate endothelial dysfunction, neuroinflammation and degeneration. Here, we review the role of cerebrovasculature dysfunction in neurodegenerative disease and discuss the potential contribution of intermittent pro-inflammatory systemic disease in causing endothelial pathology, highlighting a possible mechanism that may allow broad-spectrum therapeutic targeting in the future.
Next-generation sequencing (NGS) has revolutionized the field of rare disease diagnostics. Whole exome and whole genome sequencing are now routinely used for diagnostic purposes; however, the overall diagnosis rate remains lower than expected. In this work, we review current approaches used for calling and interpretation of germline genetic variants in the human genome, and discuss the most important challenges that persist in the bioinformatic analysis of NGS data in medical genetics. We describe and attempt to quantitatively assess the remaining problems, such as the quality of the reference genome sequence, reproducible coverage biases, or variant calling accuracy in complex regions of the genome. We also discuss the prospects of switching to the complete human genome assembly or the human pan-genome and important caveats associated with such a switch. We touch on arguably the hardest problem of NGS data analysis for medical genomics, namely, the annotation of genetic variants and their subsequent interpretation. We highlight the most challenging aspects of annotation and prioritization of both coding and non-coding variants. Finally, we demonstrate the persistent prevalence of pathogenic variants in the coding genome, and outline research directions that may enhance the efficiency of NGS-based disease diagnostics.
Low back pain due to epidural fibrosis is a major complication after spine surgery. Macrophages infiltrate the wound area post laminectomy, but the role of macrophages in epidural fibrosis remains largely elusive. In a mouse model of laminectomy, macrophage depletion decreased epidural fibrosis. CD146, an adhesion molecule involved in cell migration, is expressed by macrophages. CD146-defective macrophages exhibited impaired migration, which was mediated by reduced expression of CCR2 and suppression of the MAPK/ERK signaling pathway. CD146-defective macrophages suppress the MAPK/ERK signaling pathway by increasing Erdr1. In vivo, CD146 deficiency decreased macrophage infiltration and reduced extracellular matrix deposition in wound tissues. Moreover, the anti-CD146 antibody AA98 suppressed macrophage infiltration and epidural fibrosis. Taken together, these findings demonstrated that CD146 deficiency alleviates epidural fibrosis by decreasing the migration of macrophages via the Erdr1/ERK/CCR2 pathway. Blocking CD146 and macrophage infiltration may help alleviate epidural fibrosis.
The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional fourth type of monomers with targeting properties. The present invention also relates to core-shell or hollow shell nanoparticles coated by an external layer of the copolymer according to the invention. Several types of core-shell nanoparticles are envisaged. The invention also concerns methods for preparing said nanoparticles, as well as pharmaceutical compositions or medicaments comprising them.
PURPOSE: A pharmaceutical composition for prevention and treatment of inflammation disease containing decaspermum fruticosum extracts or asthma are provided to prevent increase of eosinocyte of bronchoalveolar lavage fluid and secretion of eotaxin and immunoglobulin of the bronchoalveolar lavage fluid and blood. CONSTITUTION: A pharmaceutical composition for prevention and treatment of inflammation disease contains decaspermum fruticosum extracts as an active ingredient. The extract is extracted using water, alcohol or a mixture thereof as a solvent. The alcohol is C1-C2 low grade alcohol. The low grade alcohol is ethanol or methanol. A manufacturing method of the decaspermum fruticosum extracts comprises the following steps: adding an extracting solvent to the decaspermum fruticosum in order to extract; filtering the extracts; vacuum concentrating the filtered extracts; and freeze-drying the condensed products. A pharmaceutical composition for prevention and treatment of asthma contains the decaspermum fruticosum extracts as an active ingredient. A health supplement for prevention and treatment of inflammation disease contains decaspermum fruticosum extracts as an active ingredient. A health supplement for prevention and treatment of asthma contains the decaspermum fruticosum extracts as an active ingredient.
PROBLEM TO BE SOLVED: To obtain the subject composition, safe to the oral cavity tissues and making a coloring substance attached to or penetrated into teeth light in color to whiten and clean them, by including ascorbic acid or its salt. SOLUTION: This composition contains 1 to 95wt.% of a combination of ascorbic acid (vitamin C) with its salt (e.g. sodium or potassium ascorbate). The composition can be incorporated with components used for common tooth powders. These include a foaming agent or foaming aid (e.g. a salt of alkylsulfuric acid ester), abrasives (e.g. calcium secondary phosphate), bulking agent (e.g. polyethylene glycol), sweetener (e.g. saccharin, to be contained at 0.05 to 10wt.% based on the ascorbic acid or its salt), preservative, microbicide, medicinal ingredient, and pH adjustor.
This invention relates to Rhodococcus equi bacteria immunogenic proteins on the bacterial cell surfaces, genetic information as it relates to the proteins and diagnostics and vaccine components based on the use of such proteins.  The DNA sequence encoding the virulent protein is described along with the corresponding amino acid sequence for the protein.  The protein, as expressed by R. equi, includes a signal peptide portion which is cleaved off in the process of the protein being excreted through the cell wall.  Also in that process, the protein is lipid modified to provide proteins of SDS-PAGE gel estimated molecular weights of 17 through 22 kDa.  A plasmid construct is provided suitable for expression in E. coli host for providing the protein.  Antibodies have been raised to the protein which are useful in diagnostic and passive vaccines. Active vaccines are provided based on the use of the protein.  The protein is hydrophobic in nature when lipid modified.  Hence, a process for recovery of the hydrophobic protein is provided which involves the use of a detergent.
The PA+BC group will be given an individualized, home-based aerobic and resistance prescription based on baseline assessment and previous work. The participants will also receive behavioural counselling support sessions with a QEP every two weeks during the intervention period (12 total). The focus of these sessions will incorporate tailored behaviour change content from the M-PAC framework. At the end of the 6-month program, an individualized PA prescription will be provided based on their fitness level (adjusted throughout) to continue achieving the PA goal for the 6-month post intervention and 1-year post intervention follow-up.
The present disclosure provides composition and methods for delivery of therapeutic biologics to locations where bile is present, including the biliary tract, and compositions and kits for use in such methods. Also provided are compositions that include, and methods that employ, biliary-therapeutic enhancers for the delivery of therapeutic biologics. Methods of biliary tract delivery of a therapeutic biologic, as described herein, generally include one or more administrations of the relevant biologic and biliary-therapeutic enhancer. Biliary delivery compositions will generally include one or more biliary-therapeutic enhancers and a therapeutic biologic. As compared to the decreased activity of the therapeutic biologic in the presence of bile, the compositions, methods, and kits of the present disclosure result in increased, enhanced and/or rescued activity of the therapeutic in the presence of bile. Use of biliary-therapeutic enhancers, e.g., in the methods, compositions and kits described, are also provided.
The invention relates to pharmaceuticals, biological physics and biodiagnostics, more specifically to preparations producing a magnetoresonance action on micro- and macro-organisms for increasing and protecting the life activity thereof in conditions of environmental pollution by individually selecting said preparations with the aid of a special device. There is no a known study on the problems of the stability of action producible on a biological object with the aid of a simple, traditionally used, multipurpose, portable and when necessary marked means for increasing the life activity of a biological object at an ecological level. For this reason, a first aim of said invention is to develop a multipurpose portable preparations for increasing the life activity of a biological object with the aid of a physiological carrier which can be marked, operate in a wide range of an electromagnetic field and steadily preserve the initial properties thereof during a long-term storage. Another aim of the invention is to develop means operational in the wide range of a variable magnetic field. The both preparations are able to increase the organism life activity improving the energy activity thereof by accelerating elimination of foreign harmful agents. The means are selected with the aid of a magnetoresonance device which detects a foreign agent if a studied organism.
Postmarketing cases of hepatic decompensation/failure, including those with fatal outcomes, have been reported in patients treated with HCV NS3/4A protease inhibitor-containing regimens, including treatment with VOSEVI. Reported cases occurred in patients with baseline cirrhosis with and without moderate or severe liver impairment (Child-Pugh B or C). Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In patients with compensated cirrhosis (Child-Pugh A) or evidence of advanced liver disease such as portal hypertension, perform hepatic laboratory testing as clinically indicated; and monitor for signs and symptoms of hepatic decompensation such as the presence of jaundice, ascites, hepatic encephalopathy, and variceal hemorrhage. Discontinue VOSEVI in patients who develop evidence of hepatic decompensation/failure.

VOSEVI is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation [see Dosage and Administration (2.4), Adverse Reactions (6.2), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].